Heparin – ACT Dynamics: Before and After “New” Heparin (Video)
Jeff Riley discusses observations from the Mayo Clinic regarding the new Heparin that is now on the market (17 minutes).
World's Largest Resource for Cardiovascular Perfusion
Jeff Riley discusses observations from the Mayo Clinic regarding the new Heparin that is now on the market (17 minutes).
Patients are being supported for longer periods with implantable left ventricular assist devices (LVADs) owing to longer transplantation wait times and approval of LVADs for destination therapy. This comes with an increased potential need for device exchange when complications arise. There are few data examining this patient population.
Correction of coagulopathy post CPB can present the surgical team with a number of challenges, including right ventricular volume overload, hemodilution, anemia and excessive cell salvage with further loss of coagulation factors.